KALV KalVista Pharmaceuticals Inc

Price (delayed)

$8.42

Market cap

$289.68M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.14

Enterprise value

$247.13M

KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary ...

Highlights
The EPS has grown by 14% YoY and by 6% from the previous quarter
KalVista Pharmaceuticals's debt has decreased by 14% YoY and by 3.9% QoQ
KALV's quick ratio is down by 40% year-on-year and by 12% since the previous quarter
KALV's equity is down by 15% year-on-year and by 13% since the previous quarter

Key stats

What are the main financial stats of KALV
Market
Shares outstanding
34.4M
Market cap
$289.68M
Enterprise value
$247.13M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.07
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$95.18M
EBITDA
-$94.36M
Free cash flow
-$79.53M
Per share
EPS
-$3.14
Free cash flow per share
-$2.31
Book value per share
$4.07
Revenue per share
$0
TBVPS
$4.66
Balance sheet
Total assets
$160.33M
Total liabilities
$21M
Debt
$6.87M
Equity
$139.34M
Working capital
$135.71M
Liquidity
Debt to equity
0.05
Current ratio
10.6
Quick ratio
8.72
Net debt/EBITDA
0.45
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-53.6%
Return on equity
-60.6%
Return on invested capital
-83.2%
Return on capital employed
-65.1%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KALV stock price

How has the KalVista Pharmaceuticals stock price performed over time
Intraday
0.72%
1 week
11.08%
1 month
5.38%
1 year
62.86%
YTD
24.56%
QTD
-12.56%

Financial performance

How have KalVista Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$113.65M
Net income
-$95.18M
Gross margin
N/A
Net margin
N/A
KALV's operating income is down by 10% YoY and by 2.5% QoQ
KalVista Pharmaceuticals's net income has decreased by 7% YoY and by 2.4% from the previous quarter

Growth

What is KalVista Pharmaceuticals's growth rate over time

Valuation

What is KalVista Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.07
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 14% YoY and by 6% from the previous quarter
The P/B is 29% higher than the last 4 quarters average of 1.6 but 17% lower than the 5-year quarterly average of 2.5
KALV's equity is down by 15% year-on-year and by 13% since the previous quarter

Efficiency

How efficient is KalVista Pharmaceuticals business performance
KalVista Pharmaceuticals's return on invested capital has shrunk by 59% YoY and by 11% QoQ
KalVista Pharmaceuticals's return on equity has decreased by 33% YoY and by 7% QoQ
The ROA fell by 28% YoY and by 6% QoQ

Dividends

What is KALV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KALV.

Financial health

How did KalVista Pharmaceuticals financials performed over time
KALV's quick ratio is down by 40% year-on-year and by 12% since the previous quarter
KalVista Pharmaceuticals's current ratio has decreased by 39% YoY and by 8% QoQ
KalVista Pharmaceuticals's debt is 95% lower than its equity
The debt to equity has grown by 25% from the previous quarter
KALV's equity is down by 15% year-on-year and by 13% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.